Last reviewed · How we verify
TYK Medicines, Inc — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
1 Phase 2
7 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| TY-9591 | TY-9591 | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes |
Therapeutic area mix
- Diabetes · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- ADvantage Therapeutics · 1 shared drug class
- AJU Pharm Co., Ltd. · 1 shared drug class
- AO GENERIUM · 1 shared drug class
- Abbott · 1 shared drug class
- AceLink Therapeutics, Inc. · 1 shared drug class
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- Aciex Therapeutics, Inc. · 1 shared drug class
- 3D Medicines (Beijing) Co., Ltd. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for TYK Medicines, Inc:
- TYK Medicines, Inc pipeline updates — RSS
- TYK Medicines, Inc pipeline updates — Atom
- TYK Medicines, Inc pipeline updates — JSON
Cite this brief
Drug Landscape (2026). TYK Medicines, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tyk-medicines-inc. Accessed 2026-05-17.